Alkermes (NASDAQ:ALKS) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $41.75, a high estimate of $45.00, and a low estimate of $34.00. Marking an increase of 7.05%, the current average surpasses the previous average price target of $39.00.

Deciphering Analyst Ratings: An In-Depth Analysis

The perception of Alkermes by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Alkermes's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Alkermes analyst ratings.

All You Need to Know About Alkermes

Alkermes: Delving into Financials

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Over the 3M period, Alkermes showcased positive performance, achieving a revenue growth rate of 4.24% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: Alkermes's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.0%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Alkermes's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.93% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): Alkermes's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.61%, the company showcases efficient use of assets and strong financial health.

Debt Management: Alkermes's debt-to-equity ratio is below the industry average. With a ratio of 0.04, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

What Are Analyst Ratings?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.